Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 43

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 8
Chunk 43
---
 then outstanding shares of common stock, with trading of the post-split shares beginning October 20,
2025. Accordingly, each 10 shares of outstanding common stock then held by our stockholders were combined into one share of common stock.
Any fractional shares resulting from the reverse split were rounded up to the next whole share. Authorized common stock was 6,000,000
shares following the stock split. The reverse stock split was effected in anticipation of, and to address, a Nasdaq notification regarding
noncompliance with the minimum bid price requirement for continued listing. The accompanying unaudited condensed consolidated financial
statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred on April 1,
2024. All shares and per share amounts have been revised accordingly.

On June 9, 2025, we effected a 1-for-8 reverse
stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding common stock then held by our stockholders
were combined into one share of common stock. Any fractional shares resulting from the reverse split were rounded up to the next whole
share. Authorized common stock remained at 60,000,000 shares following the stock split. The accompanying unaudited condensed consolidated
financial statements and accompanying notes have been retroactively revised to reflect such reverse stock split as if it had occurred
on April 1, 2024. All shares and per share amounts have been revised accordingly.

Basis of Presentation and Use of Estimates

Our accompanying unaudited condensed consolidated
financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial
information and with the instructions to Form 10-Q and Article 8 of the Securities and Exchange Commission, or SEC, Regulation S-X. Accordingly,
they should be read in conjunction with the audited financial statements and notes thereto for the fiscal year ended March 31, 2025, included
in our Annual Report on Form 10-K filed with the SEC on June 26, 2025. The accompanying unaudited condensed consolidated financial statements
include the accounts of Aethlon Medical, Inc. and its wholly owned subsidiary, Aethlon Medical Australia Pty Ltd. All significant inter-company
transactions and balances have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements,
taken as a whole, contain all adjustments that are of a normal recurring nature necessary to present fairly our operating results, cash
flows